Laser during mohs surgery may lead to Better-Looking scars
NCT ID NCT07592468
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether using a fractionated CO₂ laser on wound edges during Mohs skin cancer surgery can improve scar appearance. Fifty adults having Mohs surgery will have half their wound treated with the laser and the other half left untreated. Researchers will compare scar quality from both the patient's and doctor's perspective over time.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- CO2 Fractionated Laser
- What this could lead to
- If it works, this could offer a simple way to improve scar appearance right during skin cancer surgery, reducing the need for later treatments.
- What could go wrong
- This is a small, early-stage study with only 50 people. The laser may not improve scars significantly, and results may not apply to all skin types or healing conditions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 50 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
May 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 89 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Adults aged 18-89 years * Diagnosis of cutaneous malignancy treated with MMS * Surgical defect suitable for primary linear or flap closure with adequate length to permit split-scar design * Ability to understand and provide informed consent Exclusion Criteria: * Pregnancy * Inability to provide informed consent * Non-English speaking patients * History of abnormal wound healing (e.g., keloid disorder) * Active infection at the surgical site * Immunosuppression felt to significantly impair wound healing * Use of isotretinoin within the past 6 months * Prior radiation therapy to the surgical site * Patients belonging to vulnerable populations including prisoners, children, or individuals unable to consent
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cutaneous malignancy are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Baylor University Medical Center
Dallas, Texas, 75246, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.